Associated Papers
Transcriptional repression by a secondary DNA binding surface of DNA topoisomerase I safeguards against hypertranscription.
Lau MS et al.
Nature Communications, 2023
Cleavage-defective Topoisomerase I mutants sharply increase G-quadruplex-associated genomic instability.
Berroyer A et al.
Microbial Cell (graz, Austria), 2022
Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence.
Zhao B et al.
Nature Communications, 2020
DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM et al.
The Journal of Biological Chemistry, 2015
RECQ5-dependent SUMOylation of DNA topoisomerase I prevents transcription-associated genome instability.
Li M et al.
Nature Communications, 2015
Ligand-dependent enhancer activation regulated by topoisomerase-I activity.
Puc J et al.
Cell, 2015
Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.
Palle K et al.
The Journal of Biological Chemistry, 2008
Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.
Gurevich RM et al.
Experimental Hematology, 2006
Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin.
Ireton GC et al.
The Journal of Biological Chemistry, 2000
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Mo YY et al.
Experimental Cell Research, 2000
Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P et al.
Molecular Pharmacology, 1999
The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity.
Rossi F et al.
Nucleic Acids Research, 1998
Select a paper to view details